Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

193

VETERANS HEALTH ADMINISTRATION (VA) OUTSIDE ORGANIZATION SESSION

DIVISION OF LUNG DISEASES, NHLBI/NIH OUTSIDE ORGANIZATION SESSION

L13 GENOMICS ANALYSES FROM MILLION VETERAN PROGRAM IMPROVE LUNG CANCER DETECTION AND CARE 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 145 A-B (Street Level) Target Audience Those interested in lung cancer research and care, in VA’s Million Veteran Program, in lung cancer screening, or in treatment of those with advanced stage lung cancer with immune checkpoint inhibitors. Objectives At the conclusion of this session, the participant will be able to: • describe new findings from the Million Veteran Program and the ways that research in this large cohort could benefit the quality of life for patients with, or at risk for, lung cancer. • describe new findings about how the generation of new knowledge at the population level may be used to benefit individual patients. • describe new findings about how patients can be selected more efficiently for lung cancer screening through integrating genomics, clinical, and imaging data from individual patients. In its Million Veteran Program (MVP), VA has collected blood for genomic analysis from over 900,000 Veterans integrated with associated longitudinal clinical data. Within MVP, VA now also has conducted the largest genome-wide association study of lung cancer, identifying novel risk loci, tumor-specific signals previously masked by smoking, and polygenic risk scores for risk stratification. This work will be described along with two related applications: (1) a multiomics dashboard integrating clinical, genetic, and imaging data to improve the efficiency of selecting high-risk Veterans for screening; (2) use of genomic and phenotypic characterization to stratify those with advanced lung cancer for immunotherapy. Chairing: J.K. Brown, MD, San Francisco, CA C. Clancy, MD, Washington, D.C. 12:00 Update on the Million Veteran Program S. Muralidhar, PhD, Washington, DC 12:15 Genome-Wide Association Study of Lung Cancer in MV S. Pyarajan, PhD, Jamaica Plains, MA 12:30 Multiomic Predictive Model of Lung Cancer Risk S. Aguayo, MD, Phoenix, AZ 12:45 Predictive Model for Lung Cancer Treatment with

L14 UPDATE ON PRECLINICAL MODELS OF IPF - AN NHLBI CONSORTIUM 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 143 A-C (Street Level) Target Audience Those with research interests involving the study of idiopathic pulmonary fibrosis and other fibrotic lung diseases. Objectives At the conclusion of this session, the participant will be able to: • learn new findings regarding the pathogenesis of IPF from its onset through disease progression. • increase awareness among the broader IPF research community of the availability of new and improved model systems to study IPF. • to inform the design of research studies involving IPF by leveraging model systems uniquely suited to uncover specific types of disease mechanisms, as well as improve model selection for screening and testing new drugs/biologics that target IPF This session highlights the recent scientific advances and collaborative research achievements of an NHLBI-sponsored U01 consortium funded through RFA-HL-20-007: Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis. The goal of this initiative is to establish a set of complementary model systems that reproduce essential disease-defining features of human idiopathic pulmonary fibrosis (IPF) in order to develop more effective therapies. Chairing: M. Craig, PhD, Bethesda, MD 12:00 From Mice to iPS-AT2 and Back M.F. Beers, MD, Philadelphia, PA 12:20 Team Mesenchyme: Integrating iPSC, Matrix Biology, PCLS, and Organoids B. Gomperts, MD, Los Angeles, CA 12:40 A Novel Ferret Model of Idiopathic Pulmonary Fibrosis S.M. Rowe, MD, Birmingham, AL

Immune Checkpoint Inhibitors M. Green, MD, PhD, Ann Arbor, MI

ATS 2023 • Washington, DC